{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T11:22:25Z","timestamp":1792063345940,"version":"4.4.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.drup.2020.100719","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T11:49:53Z","timestamp":1594813793000},"page":"100719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"special_numbering":"C","title":["FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy"],"prefix":"10.1016","volume":"53","author":[{"given":"Sylwester","family":"Dro\u017cd\u017cal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Rosik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kacper","family":"Lechowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Machaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kotfis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeid","family":"Ghavami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek J.","family":"\u0141os","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2020.100719_bib0005","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1038\/cddis.2012.30","article-title":"Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers","volume":"3","author":"Adar","year":"2012","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.drup.2020.100719_bib0010","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.drup.2020.100719_bib0015","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2893.2011.01530.x","article-title":"Virus-triggered autophagy in viral hepatitis - possible novel strategies for drug development","volume":"18","author":"Alavian","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.drup.2020.100719_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.therap.2020.05.009","article-title":"Drugs acting on renin angiotensin system and use in ill patients with COVID-19","author":"Alexandre","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.drup.2020.100719_bib0025","series-title":"HFSA\/ACC\/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19","author":"American Heart","year":"2020"},{"key":"10.1016\/j.drup.2020.100719_bib0030","unstructured":"Anon 2020 https:\/\/www.thecardiologyadvisor.com\/home\/topics\/practice-management\/fda-studies-underway-to-evaluate-chloroquine-for-covid-19\/."},{"key":"10.1016\/j.drup.2020.100719_bib0035","unstructured":"Anon 2020 https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/therapeutic-options.html."},{"issue":"6","key":"10.1016\/j.drup.2020.100719_bib0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid therapy for critically ill patients with middle east respiratory syndrome","volume":"197","author":"Arabi","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s13063-017-2427-0","article-title":"Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial","volume":"19","author":"Arabi","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.drup.2020.100719_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105944","article-title":"Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?","author":"Baron","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.drup.2020.100719_bib0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1042\/CS20200163","article-title":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?","author":"Batlle","year":"2020","journal-title":"Clin. Sci."},{"key":"10.1016\/j.drup.2020.100719_bib0060","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - preliminary report","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.drup.2020.100719_bib0065","first-page":"13","article-title":"Characteristics, treatment outcomes and role of hydroxychloroquine among 522 COVID-19 hospitalized patients in Jaipur City: an epidemio-clinical study","volume":"68","author":"Bhandari","year":"2020","journal-title":"J. Assoc. Physicians India"},{"key":"10.1016\/j.drup.2020.100719_bib0070","article-title":"Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial","author":"Bian","year":"2020","journal-title":"medRxiv"},{"issue":"9","key":"10.1016\/j.drup.2020.100719_bib0075","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities","volume":"49","author":"Biot","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2020.100719_bib0080","first-page":"1","article-title":"Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine","author":"Bonam","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.drup.2020.100719_bib0085","doi-asserted-by":"crossref","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2020.100719_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with Favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.drup.2020.100719_bib0095","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"issue":"19","key":"10.1016\/j.drup.2020.100719_bib0100","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100719_bib0105","series-title":"Covid-19 And Cardiovascular Risk: Susceptibility to Infection to SARS-CoV-2, Severity and Prognosis of Covid-19 and Blockade of the Renin-angiotensin-aldosterone System. An Evidence-based Viewpoint","author":"Cappuccio","year":"2020"},{"issue":"12","key":"10.1016\/j.drup.2020.100719_bib0110","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with Lopinavir\/Ritonavir or Interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"10223","key":"10.1016\/j.drup.2020.100719_bib0115","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.drup.2020.100719_bib0120","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.1601896","article-title":"Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection","volume":"198","author":"Channappanavar","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.drup.2020.100719_bib0125","article-title":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.drup.2020.100719_bib0130","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26142","article-title":"A study on clinical effect of Arbidol combined with adjuvant therapy on COVID-19","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.drup.2020.100719_bib0135","series-title":"Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia (6 Th Edition)","author":"T.N.H.C.O.T.P.S.R.O. China","year":"2020"},{"issue":"3","key":"10.1016\/j.drup.2020.100719_bib0140","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.drup.2020.100719_bib0145","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/cid\/ciy319","article-title":"Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria","volume":"67","author":"Chu","year":"2018","journal-title":"Clin. Infect. Dis."},{"issue":"S4","key":"10.1016\/j.drup.2020.100719_bib0150","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1111\/hiv.12426","article-title":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015","volume":"17","author":"Churchill","year":"2016","journal-title":"HIV Med."},{"issue":"3708","key":"10.1016\/j.drup.2020.100719_bib0155","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1126\/science.151.3708.347","article-title":"Chloroquine: mode of action","volume":"151","author":"Ciak","year":"1966","journal-title":"Science"},{"key":"10.1016\/j.drup.2020.100719_bib0160","series-title":"China Approves Use of Roche arthritis Drug for COVID-19 Patients","author":"Cna","year":"2020"},{"issue":"19","key":"10.1016\/j.drup.2020.100719_bib0165","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.drup.2020.100719_bib0170","series-title":"New England Journal of Medicine","author":"Compassionate Use of Remdesivir in Covid-19","year":"2020"},{"key":"10.1016\/j.drup.2020.100719_bib0175","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.drup.2020.100719_bib0180","doi-asserted-by":"crossref","first-page":"104742","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antiviral Res."},{"issue":"7378","key":"10.1016\/j.drup.2020.100719_bib0185","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature10606","article-title":"Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum","volume":"480","author":"Crosnier","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drup.2020.100719_bib0190","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drup.2020.100719_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against Corona Virus Disease 2019:a retrospective cohort study","author":"Deng","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.drup.2020.100719_bib0200","first-page":"1","article-title":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics","author":"Dhama","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.drup.2020.100719_bib0205","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","author":"Diaz","year":"2020","journal-title":"J. Travel Med."},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0210","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"issue":"Rr-7","key":"10.1016\/j.drup.2020.100719_bib0215","first-page":"1","article-title":"Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV","volume":"51","author":"Dybul","year":"2002","journal-title":"MMWR Recomm. Rep."},{"issue":"23","key":"10.1016\/j.drup.2020.100719_bib0220","first-page":"1429","article-title":"Results of the cooperative north scandinavian enalapril survival study (CONSENSUS)","volume":"316","author":"Effects of enalapril on mortality in severe congestive heart failure","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100719_bib0225","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000000797","article-title":"Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model","author":"Fan","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"20","key":"10.1016\/j.drup.2020.100719_bib0230","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.drup.2020.100719_bib0235","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.11301","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality","author":"Fosb\u00f8l","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0240","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.drup.2020.100719_bib0245","first-page":"1","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"7","key":"10.1016\/j.drup.2020.100719_bib0250","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.bbamcr.2014.03.006","article-title":"Airway mesenchymal cell death by mevalonate cascade inhibition: integration of autophagy, unfolded protein response and apoptosis focusing on Bcl2 family proteins","volume":"1843","author":"Ghavami","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.drup.2020.100719_bib0255","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ahj.2020.05.010","article-title":"Rationale and design of the PRAETORIAN-COVID trial: a double-blind, placebo-controlled randomized clinical trial with valsartan for PRevention of Acute rEspiraTORy dIstress syndrome in hospitAlized patieNts with SARS-COV-2 Infection Disease","volume":"226","author":"Gommans","year":"2020","journal-title":"Am. Heart J."},{"key":"10.1016\/j.drup.2020.100719_bib0260","article-title":"Severe acute respiratory syndrome-related coronavirus: the species and its viruses - a statement of the Coronavirus Study Group","author":"Gorbalenya","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.drup.2020.100719_bib0265","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100719_bib0270","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.drup.2020.100719_bib0275","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.drup.2020.100719_bib0280","series-title":"Coronavirus Puts Drug Repurposing on the Fast Track","author":"Harrison","year":"2020"},{"key":"10.1016\/j.drup.2020.100719_bib0285","article-title":"The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells","author":"Hoffmann","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.drup.2020.100719_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.drup.2020.100719_bib0295","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10223","key":"10.1016\/j.drup.2020.100719_bib0300","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2020.100719_bib0305","article-title":"Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis","author":"Huang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.drup.2020.100719_bib0310","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.antiviral.2018.01.002","article-title":"The role of adjuvant immunomodulatory agents for treatment of severe influenza","volume":"150","author":"Hui","year":"2018","journal-title":"Antiviral Res."},{"issue":"10238","key":"10.1016\/j.drup.2020.100719_bib0315","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.drup.2020.100719_bib0320","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12827","article-title":"Pharmacokinetics of Favipiravir in critically ill patients with COVID-19","author":"Irie","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.drup.2020.100719_bib0325","doi-asserted-by":"crossref","DOI":"10.1177\/2040206618764483","article-title":"Nucleosides for the treatment of respiratory RNA virus infections","volume":"26","author":"Jordan","year":"2018","journal-title":"Antivir. Chem. Chemother."},{"issue":"13","key":"10.1016\/j.drup.2020.100719_bib0330","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2165\/00003495-200767130-00011","article-title":"Telbivudine","volume":"67","author":"Keam","year":"2007","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.drup.2020.100719_bib0335","doi-asserted-by":"crossref","first-page":"e1005531","DOI":"10.1371\/journal.ppat.1005531","article-title":"Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor","volume":"12","author":"Kim","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.drup.2020.100719_bib0340","doi-asserted-by":"crossref","first-page":"105933","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","author":"Ko","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"2","key":"10.1016\/j.drup.2020.100719_bib0345","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5114\/ait.2020.95164","article-title":"COVID-19: what do we need to know about ICU delirium during the SARS-CoV-2 pandemic?","volume":"52","author":"Kotfis","year":"2020","journal-title":"Anaesthesiol. Intensive Ther."},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0350","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13054-020-02882-x","article-title":"COVID-19: ICU delirium management during SARS-CoV-2 pandemic","volume":"24","author":"Kotfis","year":"2020","journal-title":"Crit. Care"},{"issue":"20","key":"10.1016\/j.drup.2020.100719_bib0355","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1056\/NEJMoa030781","article-title":"A novel coronavirus associated with severe acute respiratory syndrome","volume":"348","author":"Ksiazek","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100719_bib0360","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2017.02.007","article-title":"Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL(Pro) inhibitors","volume":"141","author":"Kumar","year":"2017","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2020.100719_bib0365","article-title":"WHO launches global megatrial of the four most promising coronavirus treatments","volume":"22","author":"Kupferschmidt","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.drup.2020.100719_bib0370","series-title":"Antimalarial Agents: Closing the Gate on Toll-like Receptors?","first-page":"3068","author":"Lafyatis","year":"2006"},{"issue":"6","key":"10.1016\/j.drup.2020.100719_bib0375","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.3390\/jcm9061917","article-title":"COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection","volume":"9","author":"Lechowicz","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.drup.2020.100719_bib0380","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","article-title":"Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients","volume":"31","author":"Lee","year":"2004","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.drup.2020.100719_bib0385","article-title":"Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig","author":"Lei","year":"2020","journal-title":"bioRxiv"},{"issue":"6965","key":"10.1016\/j.drup.2020.100719_bib0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.drup.2020.100719_bib0395","first-page":"170","article-title":"[Potential antiviral therapeutics for 2019 Novel Coronavirus]","volume":"43","author":"Li","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"issue":"7","key":"10.1016\/j.drup.2020.100719_bib0400","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cmi.2020.04.026","article-title":"Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study","volume":"26","author":"Lian","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.drup.2020.100719_bib0405","article-title":"Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression","author":"Liu","year":"2020","journal-title":"Int. J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0410","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41467-018-05763-8","article-title":"Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy","volume":"9","author":"Logue","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0415","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","article-title":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)","volume":"14","author":"Lu","year":"2020","journal-title":"Biosci. Trends"},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0420","doi-asserted-by":"crossref","DOI":"10.1186\/s12985-018-1050-3","article-title":"Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV\/HIV coinfection: a meta-analysis","volume":"15","author":"Luo","year":"2018","journal-title":"Virol. J."},{"key":"10.1016\/j.drup.2020.100719_bib0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing clinical trials for the management of the COVID-19 pandemic","author":"Lythgoe","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.drup.2020.100719_bib0430","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0435","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12967-020-02364-2","article-title":"The urgent need for integrated science to fight COVID-19 pandemic and beyond","volume":"18","author":"Moradian","year":"2020","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drup.2020.100719_bib0440","article-title":"Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study","author":"Morales","year":"2020","journal-title":"medRxiv : the preprint server for health sciences"},{"issue":"5","key":"10.1016\/j.drup.2020.100719_bib0445","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"ChemBioChem"},{"key":"10.1016\/j.drup.2020.100719_bib0450","first-page":"1","article-title":"SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review","author":"Nascimento","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"issue":"4","key":"10.1016\/j.drup.2020.100719_bib0455","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1084\/jem.162.4.1371","article-title":"Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from alpha-beta dimers in B cells","volume":"162","author":"Nowell","year":"1985","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drup.2020.100719_bib0460","series-title":"Guidelines for the Care and Treatment of Persons Diagnosed With Chronic Hepatitis C Virus Infection","author":"Organization","year":"2018"},{"key":"10.1016\/j.drup.2020.100719_bib0465","first-page":"1","article-title":"Lopinavir-ritonavir in the treatment of COVID-19: a dynamic systematic benefit-risk assessment","author":"Osborne","year":"2020","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0470","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2020.100719_bib0475","series-title":"PharmaMar Reports Positive Results for Aplidin \u00ae Against Coronavirus HCoV-229E","author":"Pharmamar","year":"2020"},{"key":"10.1016\/j.drup.2020.100719_bib0480","series-title":"Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19 (APLICOV-PC)","author":"PharmaMar","year":"2020"},{"issue":"2","key":"10.1016\/j.drup.2020.100719_bib0485","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2055-6640(20)30016-9","article-title":"A review of the safety of favipiravir\u2013a potential treatment in the COVID-19 pandemic?","volume":"6","author":"Pilkington","year":"2020","journal-title":"J. Virus Erad."},{"issue":"8","key":"10.1016\/j.drup.2020.100719_bib0490","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"10.1016\/j.drup.2020.100719_bib0495","first-page":"1177","article-title":"Zidovudine (Retrovir) update","volume":"143","author":"Rachlis","year":"1990","journal-title":"CMAJ"},{"issue":"10223","key":"10.1016\/j.drup.2020.100719_bib0500","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russell","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2020.100719_bib0505","doi-asserted-by":"crossref","first-page":"104791","DOI":"10.1016\/j.antiviral.2020.104791","article-title":"Type 1 interferons as a potential treatment against COVID-19","author":"Sallard","year":"2020","journal-title":"Antiviral Res."},{"issue":"6","key":"10.1016\/j.drup.2020.100719_bib0510","first-page":"417","article-title":"High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial","volume":"9","author":"Schwartz","year":"2003","journal-title":"Am. J. Manag. Care"},{"issue":"396","key":"10.1016\/j.drup.2020.100719_bib0515","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0520","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/21505594.2020.1780088","article-title":"Autophagy and SARS-CoV-2 infection: apossible smart targeting of the autophagy pathway","volume":"11","author":"Shojaei","year":"2020","journal-title":"Virulence"},{"issue":"5","key":"10.1016\/j.drup.2020.100719_bib0525","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/febs.15069","article-title":"Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes","volume":"287","author":"Shojaei","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.drup.2020.100719_bib0530","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1863","article-title":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence","author":"Sriram","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.drup.2020.100719_bib0535","first-page":"219","article-title":"[Inhibitors of RAS might Be a good choice for the therapy of COVID-19 pneumonia]","volume":"43","author":"Sun","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.drup.2020.100719_bib0540","unstructured":"Kwak Sung-sun Physicians work out treatment guidelines for coronavirus. [cited 2020 27.03]; http:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=7428."},{"key":"10.1016\/j.drup.2020.100719_bib0545","doi-asserted-by":"crossref","first-page":"173288","DOI":"10.1016\/j.ejphar.2020.173288","article-title":"Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?","volume":"882","author":"Sureda","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drup.2020.100719_bib0550","article-title":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","volume":"369","author":"Tang","year":"2020","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.drup.2020.100719_bib0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102568","article-title":"Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy","volume":"19","author":"Toniati","year":"2020","journal-title":"Autoimmun. Rev."},{"issue":"21","key":"10.1016\/j.drup.2020.100719_bib0560","first-page":"e68","article-title":"Lopinavir\u2013Ritonavir in Covid-19","volume":"382","author":"Trial of","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drup.2020.100719_bib0565","series-title":"ClinicalTrials.gov","author":"US National Library of Medicine","year":"2020"},{"key":"10.1016\/j.drup.2020.100719_bib0570","doi-asserted-by":"crossref","first-page":"165889","DOI":"10.1016\/j.bbadis.2020.165889","article-title":"SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets","author":"Vallamkondu","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.drup.2020.100719_bib0575","series-title":"Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-nCoV) in Vitro","first-page":"269","author":"Wang","year":"2020"},{"issue":"10236","key":"10.1016\/j.drup.2020.100719_bib0580","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.drup.2020.100719_bib0585","article-title":"SARS-CoV-2 invades host cells via a novel route: CD147-spike protein","author":"Wang","year":"2020","journal-title":"bioRxiv"},{"issue":"7594","key":"10.1016\/j.drup.2020.100719_bib0590","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.drup.2020.100719_bib0595","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00203-20","article-title":"COVID-19: knowns, unknowns, and questions","volume":"5","author":"Weston","year":"2020","journal-title":"mSphere"},{"key":"10.1016\/j.drup.2020.100719_bib0600","series-title":"Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection Is Suspected","first-page":"1","author":"Who","year":"2020"},{"key":"10.1016\/j.drup.2020.100719_bib0605","series-title":"WHO Discontinues Hydroxychloroquine and lopinavir\/ritonavir Treatment Arms for COVID-19","author":"WHO","year":"2020"},{"key":"10.1016\/j.drup.2020.100719_bib0610","doi-asserted-by":"crossref","first-page":"m2610","DOI":"10.1136\/bmj.m2610","article-title":"Covid-19: remdesivir is recommended for authorisation by European Medicines Agency","volume":"369","author":"Wise","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.drup.2020.100719_bib0615","series-title":"Clinical Management of COVID-19","author":"World Health","year":"2020"},{"issue":"5","key":"10.1016\/j.drup.2020.100719_bib0620","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1191\/0961203306lu2299oa","article-title":"Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients","volume":"15","author":"Wozniacka","year":"2006","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.drup.2020.100719_bib0625","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aav4580","article-title":"A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike","volume":"5","author":"Xia","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2020.100719_bib0630","article-title":"Combination antiviral therapy with lopinavir\/ritonavir","author":"Xie","year":"2020","journal-title":"arbidol and interferon-\u03b11b for COVID-19."},{"key":"10.1016\/j.drup.2020.100719_bib0635","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s11427-020-1637-5","article-title":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","author":"Xu","year":"2020","journal-title":"Sci. China Life Sci."},{"issue":"4-5","key":"10.1016\/j.drup.2020.100719_bib0640","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.micinf.2020.05.012","article-title":"Arbidol\/IFN-\u03b12b therapy for patients with corona virus disease 2019: a retrospective multicenter cohort study","volume":"22","author":"Xu","year":"2020","journal-title":"Microbes Infect."},{"issue":"00026","key":"10.1016\/j.drup.2020.100719_bib0645","first-page":"v1","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"202003","author":"Xu","year":"2020","journal-title":"ChinaXiv"},{"key":"10.1016\/j.drup.2020.100719_bib0650","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0655","first-page":"1","article-title":"Asthma and influenza virus infection:focusing on cell death and stress pathways in influenza virus replication","volume":"12","author":"Yeganeh","year":"2013","journal-title":"Iran. J. Allergy Asthma Immunol."},{"issue":"3","key":"10.1016\/j.drup.2020.100719_bib0660","doi-asserted-by":"crossref","first-page":"L270","DOI":"10.1152\/ajplung.00011.2014","article-title":"Suppression of influenza A virus replication in human lung epithelial cells by noncytotoxic concentrations bafilomycin A1","volume":"308","author":"Yeganeh","year":"2015","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"2","key":"10.1016\/j.drup.2020.100719_bib0665","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbamcr.2017.10.014","article-title":"Autophagy activation is required for influenza A virus-induced apoptosis and replication","volume":"1865","author":"Yeganeh","year":"2018","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.drup.2020.100719_bib0670","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13578-020-00404-4","article-title":"SARS-CoV-2 and COVID-19: the most important research questions","volume":"10","author":"Yuen","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.drup.2020.100719_bib0675","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-05985-9","article-title":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target","author":"Zhang","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.drup.2020.100719_bib0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2020.06.015","article-title":"In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19","author":"Zhang","year":"2020","journal-title":"Cell Metab."},{"issue":"2","key":"10.1016\/j.drup.2020.100719_bib0685","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.18632\/oncotarget.2732","article-title":"Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance","volume":"6","author":"Zhitomirsky","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drup.2020.100719_bib0690","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2015.11.004","article-title":"Lysosomes as mediators of drug resistance in cancer","volume":"24","author":"Zhitomirsky","year":"2016","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.drup.2020.100719_bib0695","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.drup.2020.100719_bib0700","series-title":"Discovery of a Novel Coronavirus Associated With the Recent Pneumonia Outbreak in Humans and Its Potential Bat Origin","author":"Zhou","year":"2020"},{"issue":"1","key":"10.1016\/j.drup.2020.100719_bib0705","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."},{"issue":"5","key":"10.1016\/j.drup.2020.100719_bib0710","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764620300480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764620300480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T04:59:22Z","timestamp":1761281962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764620300480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":142,"alternative-id":["S1368764620300480"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2020.100719","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2020.100719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100719"}}